Tirasemtiv
Names
[ CAS No. ]:
1005491-05-3
[ Name ]:
Tirasemtiv
[Synonym ]:
Tirasemtiv (USAN/INN)
6-Ethynyl-1-(3-pentanyl)-1,3-dihydro-2H-imidazo[4,5-b]pyrazin-2-one
Tirasemtiv
Tirasemtiv [INN]
UNII-G8WSM7R635
1H-Imidazo[4,5-b]pyrazin-2-ol, 1-(1-ethylpropyl)-6-ethynyl-
Biological Activity
[Description]:
Tirasemtiv is an activator of the fast skeletal muscle troponin complex.
[Related Catalog]:
[Target]
[In Vitro]
Tirasemtiv is a fast skeletal troponin activator that sensitizes the sarcomere to calcium; this mechanism of action amplifies the response of muscle to neuromuscular input producing greater force when nerve input is reduced. Tirasemtiv selectively sensitizes fast skeletal muscle troponin to calcium (Ca2+), and slows the rate of Ca2+ release from the regulatory troponin complex of fast skeletal muscle[1].
[In Vivo]
A single dose of Tirasemtiv significantly increases submaximal isometric force, forelimb grip strength, grid hang time, and rotarod performance in a female transgenic mouse model (B6SJL-SOD1G93A) of ALS with functional deficits. Additionally, diaphragm force and tidal volume are significantly higher in Tirasemtiv-treated female B6SJL-SOD1G93A mice. At the 25% deficit milestone, vehicle-treated B6SJL-SOD1G93A mice demonstrated forelimb grip strength of 49.6±4.6 g. Tirasemtiv increases grip strength by 38% to 68.6±8.1g (p<0.05, single tailed t-test). Tirasemtiv doses of 2, 2, 2, and 4 mg/kg given at approximately 20 min intervals to achieve a cumulative dose of 10 mg/kg. Regression analysis of the log dose vs. response relationship indicated that Tirasemtiv significantly increased muscle force in WT and mid-stage B6SJL-SOD1G93A mice (WT p<0.0001; mid-stage p=0.0028). At later stages of disease, the mice exhibited a trend for increased muscle function in response to Tirasemtivcompared to baseline (p=0.064)[1].
[Animal admin]
Mice[1] Wild-type background strain B6SJLF1/J mice and B6SJL-SOD1G93A mice over-expressing the human SOD-1 gene with mutation G93A are group-housed in a 12-hour light cycle and fed standard chow and water ad libitum. Tirasemtiv is administered in solution (50% PEG300/10% EtOH/40% Cavitron cyclodextrin formulation) as a single slow bolus over a 2 minute period via a catheter in the contralateral femoral artery placed above the aortic bifurcation. Tirasemtiv bolus injections (2, 2, 2, and 4 mg/kg) are given at approximately 20 min intervals to achieve a cumulative dose of 10 mg/kg in order to assess the dose response, with a maximal dosage volume of 5 mL/kg. At the end of each experiment, a single terminal blood sample is drawn via cardiac puncture for compound concentration analysis.
[References]
[Related Small Molecules]
Chemical & Physical Properties
[ Density]:
1.2±0.1 g/cm3
[ Boiling Point ]:
422.3±55.0 °C at 760 mmHg
[ Molecular Formula ]:
C12H14N4O
[ Molecular Weight ]:
230.266
[ Flash Point ]:
209.2±31.5 °C
[ Exact Mass ]:
230.116760
[ PSA ]:
63.57000
[ LogP ]:
1.54
[ Appearance of Characters ]:
white solid
[ Vapour Pressure ]:
0.0±1.0 mmHg at 25°C
[ Index of Refraction ]:
1.620
[ Storage condition ]:
-20℃
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.